



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
--------------------	-------------	-----------------------	---------------------

08/908469

EXAMINER

ART UNIT	PAPER NUMBER
----------	--------------

26

DATE MAILED:

INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel):

- (1) LARRY HERMS (PTO) (3) MS. LEE (APP. REF)
(2) MR. CUI (APP. REF) (4) _____

Date of Interview 8/15/01

Type: ☐ Telephonic ☒ Personal (copy is given to ☐ applicant ☒ applicant's representative).

Exhibit shown or demonstration conducted: ☐ Yes ☐ No If yes, brief description: _____

Agreement ☐ was reached. ☒ was not reached.

Claim(s) discussed: Claims 34-42

Identification of prior art discussed: NONE

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: _____

DISCUSSED DRAFT CLAIMS. CLAIM SEEM TO HAVE SUPPORT IN
APPLICATION AS ORIGINALLY FILED. SEE ATTACHED

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☒ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Examiner Note: You must sign this form unless it is an attachment to another form.

[Signature] 8/15/01

USSN 08/908,469

DRAFT -- FOR DISCUSSION PURPOSES ONLY
--NOT FOR ENTRY IN THE RECORD--

Draft Claim Amendments
U.S. Serial No. 08/908,469 (P1093P1)

34. (AMENDED) Isolated nucleic acid encoding a humanized anti-VEGF antibody which:
~~binds human VEGF with a K_d value of no more than about 1×10^{-8} M~~

(a) binds human VEGF with a K_d value of about 1×10^{-8} M or better affinity;

(b) has an ED50 value of no more than about 5nM for inhibiting VEGF-induced proliferation of endothelial cells *in vitro*; and

(c) inhibits VEGF-induced angiogenesis *in vivo*, wherein 5mg/kg of the antibody inhibits at least about 50% of tumor growth in an A673 *in vivo* tumor model.

35. A vector comprising the nucleic acid of claim 34.

36. A host cell comprising the vector of claim 35.

37. A process of producing a humanized anti-VEGF antibody comprising culturing the host cell of claim 36 so that the nucleic acid is expressed.

38. The process of claim 37 further comprising recovering the humanized anti-VEGF antibody from the host cell culture.